ArticleJournal of translational medicine2026
Integrated single-cell and spatial transcriptomics uncover SPP1⁺ and HLA-DRB5⁺ macrophages as key modulators of the immune microenvironment in colorectal cancer liver metastasis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multimodal prediction of metachronous liver metastasis in stage I-III colorectal cancer patients: multicenter cohort study employing machine learning.Abdominal radiology (New York) · 2026Article
- Heterogeneity of macrophages in PD-1/PD-L1 inhibitor therapy: a single-cell perspective.Cellular & molecular biology letters · 2026Review
- Colorectal cancer liver metastasis: immunosuppressive microenvironment, signaling pathways, and emerging therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundLiver metastasis is the leading cause of mortality in colorectal cancer (CRC), yet the phenotypic diversity and spatial organization of myeloid cells in this setting remain unclear.
methodsPublicly available single-cell RNA sequencing, spatial transcriptomic, and bulk transcriptomic datasets from CRC and liver metastasis were integrated. Single-cell analyses were performed to characterize myeloid cell heterogeneity, differentiation trajectories, and inferred intercellular communication, while spatial transcriptomic analyses were conducted to assess cell-type enrichment and inferred spatial relationships. Differential expression and survival analyses were combined to construct an HLA-DRB5⁺ macrophage-associated prognostic signature, which was validated across multiple independent cohorts.
resultsEleven myeloid cell subsets were identified, among which SPP1⁺ and HLA-DRB5⁺ macrophages were markedly enriched in liver metastases and occupied distinct positions along myeloid differentiation trajectories. Cell–cell communication analysis revealed distinct predicted signaling patterns, with SPP1⁺ macrophages interacting with B cells and regulatory T cells through MIF–(CD74 + CXCR4) signaling, and HLA-DRB5⁺ macrophages communicating with T and NK cells via LGALS9–CD45 signaling. Spatial transcriptomic analyses demonstrated distinct localization patterns of these macrophage subsets across tumor, stromal, and hepatocyte regions, and MISTy-based analysis identified dynamic spatial associations with immune and stromal populations. In addition, a six-gene prognostic signature derived from HLA-DRB5⁺ macrophage-associated genes exhibited robust and independent predictive performance for overall survival across multiple CRC cohorts.
conclusionsThis integrative multi-omics analysis reveals distinct transcriptional and spatial features of SPP1⁺ and HLA-DRB5⁺ macrophages in CRC liver metastasis and highlights their potential roles in shaping the metastatic immune microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.